Serono Sues Cell Genesys Over TKT Gene Activation Patent

Law360, New York (September 1, 2004, 12:00 AM EDT) -- A subsidiary of Switzerland’s Serono has sued Transkaryotic Therapies (TKT) licensee Cell Genesys, alleging that gene activation technology used in the production of TKT’s biological drugs infringes a U.S. patent.

Serono’s subsidiary, Applied Research Systems, filed the amended complaint in the U.S. District Court for the District of Massachusetts, claiming infringement of its U.S. patent No. 5,272,071.

In the original complaint, Serono appealed a U.S. Patent and Trademark Office decision that 34 of the claims of the '071 patent are invalid.

Serono and Cell Genesys were...
To view the full article, register now.